In Vitro Diagnostics Business Outlook, Volume 3, Issue 2 - Focus on Immunoassay Overview
21 Mar 2024
In Vitro Diagnostics Business Outlook is a bimonthly publication with six issues annually.
In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:
- Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
- A comprehensive view of the IVD market with test categories covered and company briefs
- M&A activities, selected partnerships & collaborations, partnership deals, and more
- Industry & region watch to help tailor strategies
- Analysis of news and events and reporting on news not easily available
Table of Contents
-
Market Analysis
- Overview of IVD Immunoassay
- Market Outlook
- Regional Market
-
Top Company Briefs
- Roche
- Abbott Diagnostics
- Siemens Healthineers
- Other Selected Immunoassay News
-
Executive News Briefing
- Freenome Raises $254 Million in New Funding
- QuidelOrtho Axes CEO
- Agilent CEO to Retire
-
Financial Highlights: Bio-Rad Laboratories and Veracyte
- Veracyte Reported Strong Performance in 2023
-
Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Mergers and Acquisitions
- Partnerships and Collaborations
-
Industry Watch
- Virus Testing Update
-
Region Watch
- South Africa
-
Broad-based Company Announcements
- Werfen Receives CE Mark for Aptiva Antiphospholipid Syndrome
- DiaSorin Nabs FDA Clearance for New LIAISON PLEX System
- T2 Biosystems Offers Expanded Panel
- Cepheid Received FDA Clearance for Xpert Xpress GBS
- DiaCarta Collaboration to Launch Prostate Cancer LDT